TransEnterix,
Inc. (NYSE MKT:TRXC),
a medical device company that is pioneering the use of robotics and
flexible instruments to improve minimally invasive surgery, today
announced it intends to offer shares of its common stock in an
underwritten public offering. The offering is subject to market and
other conditions, and there can be no assurance as to whether or when
the offering may be completed or as to the actual size or terms of the
offering. TransEnterix plans to use the net proceeds from this offering
for research and development, sales, marketing, and commercialization
related to its SurgiBot™ System, working capital and other general
corporate purposes.
Stifel and RBC Capital Markets are acting as the joint book-running
managers and Raymond James and BTIG are acting as co-managers for the
offering.
This offering is being made pursuant to a preliminary prospectus
supplement and accompanying prospectus dated December 19, 2014, filed as
part of TransEnterix’s effective $100 million shelf registration
statement. Copies of the preliminary prospectus supplement and
accompanying prospectus relating to these securities may be obtained by
contacting Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street, Suite 3700, San Francisco, California
94104, by calling (415) 364-2720 or by emailing Syndprospectus@stifel.com,
or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY
10281-8098, Attention: Equity Syndicate, by calling (877) 822-4089 or by
emailing equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
jurisdiction.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of
robotics and flexible instruments to improve minimally invasive surgery
by addressing the economic and clinical challenges associated with
current laparoscopic and robotic options. The company is focused on the
development and commercialization of the SurgiBot System, a robotically
enhanced laparoscopic surgical platform that allows the surgeon to be
patient-side within the sterile field.
Forward Looking Statements
This press release includes statements relating to the proposed
offering of our common stock. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established by
the Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to differ
materially from expectations and include our expectations regarding the
proposed offering and use of proceeds. For a discussion of the most
significant risks and uncertainties associated with TransEnterix's
business, please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the year
ended December 31, 2014 and subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of this
press release and speak only as of the date of this press release. We
undertake no obligation to publicly update or revise any forward looking
statement, whether as a result of new information, future events or
otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150608005667/en/
Copyright Business Wire 2015